According to the biotech Enanta, you can count Novartis out of the race to develop next-gen hepatitis C cocktails. The pharma giant has bowed out of its partnership with Enanta on an NS5A inhibitor code-named EDP-239, which attracted a $440 million deal--including $36 million upfront--back in 2012.
GlaxoSmithKline is expanding its efforts to encourage research into bioelectronic medicine, putting up $5 million to support R&D projects around the world.
Johnson & Johnson is taking a deep dive into antivirals, trading $1.75 billion for private biotech Alios BioPharma to get its hands on a midstage treatment and some early assets that could expand its share of the blockbuster hepatitis C market.
Regeneron and partner Sanofi have notched another midstage milestone with their in-development allergy drug, a victory that affirms the hypothesis behind a treatment the companies believe could bring in billions.
A study published Sept. 29 in The Journal of the American Medical Association concluded that publicly available information to support the safety and effectiveness of implanted, 510(k)-cleared devices is lacking.
Four months after it signed an option pact that included $33 million in an upfront and early milestone, along with $468 million in add-on incentives, Takeda has agreed to pay the freight on researching up to four more MacroGenics programs while adding up to $400 million each--$1.6 billion in total--in fresh milestones.
Chicago-based Baxter International has inked a 200,000-square-foot lease in the heart of Cambridge, MA's biotech hub which will become the new research center of its soon-to-be-spun-out biopharma division, Baxalta.
Nightscout touts itself as an open source, do-it-yourself project to enable remote monitoring of blood glucose levels of patients with Type 1 diabetes.
Thanks to engineers at Oregon State University, people who have lost the use of their hands due to nerve trauma or a stroke might get their grip back with a simple pulley mechanism.
AstraZeneca is looking to bring more of its IT work in-house, spending money to stand up an Indian hub that will replace much of its contract spend in the field.